期刊文献+

抗血管内皮生长因子治疗无应答的遗传学因素研究现状 被引量:2

The genetic factors of non-response to anti-vascular endothelial growth factor therapy
原文传递
导出
摘要 抗血管内皮生长因子(VEGF)的疗效存在个体差异.根据功能及形态变化,抗VEGF治疗的应答程度可分为理想应答、弱应答、无应答3种情况.导致机体无应答的原因尚未明确,可能的影响因素包括年龄、基线视力、疾病病程、病灶特点及基因的多态性等.目前对于导致抗VEGF无应答遗传因素的研究主要集中在VEGF相关基因、补体因子H、年龄相关性黄斑病变易感因子2、高温必需因子A-1及白介素相关基因等.本文通过综合抗VEGF药物治疗无应答相关遗传学因素研究,进一步分析导致抗VEGF无应答的遗传机制,以期为临床制定个性化治疗方案和预测抗VEGF疗效研究提供参考. The response to anti-vascular endothelial growth factor (VEGF) treatment is variable.It is generally measured in terms of changes in correlated functional and/or anatomical outcomes,and patients are then classified as optimal response,poor response and non-response.The precise cause of non-response remains undetermined.A variety of factors could account for poor or non-response to anti-VEGF therapy,such as age,baseline vision,disease course,lesion characteristics and genomic polymorphism.At the present time,many studies on the genetic factors of non-response or poor response to anti-VEGF treatment mainly focus on VEGF genes (VEGF-A,VEGFR-2),complement factor H (CFH),age-related maculopathy susceptibility 2 (LOC387715/ARMS2),high temperature factor A-1 (HTRA1),interleukin-related gene (IL-8 rs4073) and so forth.It is still worthy of further investigations that how to assess genetic reasons for non-response or poor response,so that we can provide individualized treatment sequences and predict the response to anti-VEGF therapy.
作者 许淑霞 黄世威 苏冠方 Xu Shuxia;Huang Shiwei;Su Guanfang(Eye Center of the Second Hospital,Jilin University,Changchun 130022,China)
出处 《中华眼科杂志》 CAS CSCD 北大核心 2018年第11期873-878,共6页 Chinese Journal of Ophthalmology
关键词 血管内皮生长因子A 血管生成抑制剂 医疗无效 多态性 单核苷酸 vascular endothelial growth factor A angiogenesis inhibitors medical futility polymorphism,single nucleotide
  • 相关文献

参考文献3

二级参考文献37

  • 1Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration [ J ]. N Engl J Med, 2006,355 : 1419-1431.
  • 2Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials [ J ]. Br J Ophthalmol, 2010,94 : 2 -13.
  • 3Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trims [ J ]. Ophthalmology, 2011,118 : 523- 530.
  • 4Bressler NM, Chang TS, Suffer I J, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye : clinical trial results from MARINA and ANCHOR [ J ]. Ophthalmology, 2010,117:747-756.
  • 5Bopp S. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy? [ J ]. Br J Ophthalmol,2007,91 : 1259- 1260.
  • 6Otsuji T, Nagai Y, Sho K, et al. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD) [ J ]. Clin Ophthalmo1,2013,7 : 1487-1490.
  • 7Ciardella AP, Donsoff IM, Huang S J, et al. Polypoidal choroidal vasculopathy [J]. Surv Ophthalmol,2004,49 : 25-37.
  • 8Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients [ J ]. Am J Ophthalmol,2007,144 : 15-22.
  • 9Wen F, Chen C, Wu D, et al. Polypoidal chomidal vasculopathy in elderly Chinese patients [J]. Graefes Arch Clin Exp Ophthalmol, 2004,242 : 625 4529.
  • 10Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vaseulopathy [ J ]. Retina,2012,32 : 1453-1464.

共引文献20

同被引文献16

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部